An Open-Label Phase 1/2 Study of Itacitinib in Combination With Osimertinib in Subjects With Non-Small Cell Lung Cancer
Incyte Corporation
Incyte Corporation
Big Ten Cancer Research Consortium
Exelixis
NantCell, Inc.
M.D. Anderson Cancer Center
Shanghai Escugen Biotechnology Co., Ltd
Incyte Corporation
Navigation Sciences, Inc.
National Institutes of Health Clinical Center (CC)
City of Hope Medical Center
Hoffmann-La Roche
Gustave Roussy, Cancer Campus, Grand Paris
Akeso
Intensity Therapeutics, Inc.
Ultimovacs ASA
Memorial Sloan Kettering Cancer Center
NextCure, Inc.
Mural Oncology, Inc
Capital Medical University
Humanetics Corporation
Apexigen America, Inc.
Yale University
M.D. Anderson Cancer Center
Canadian Cancer Trials Group
Canadian Cancer Trials Group
Klus Pharma Inc.
Revolution Medicines, Inc.
Eisai Inc.
G1 Therapeutics, Inc.
LYZZ Alpha Holding Ltd
Radiation Therapy Oncology Group
Kiadis Pharma
Incyte Corporation
Incyte Corporation
Daiichi Sankyo
Seagen Inc.
Centre hospitalier de l'Université de Montréal (CHUM)
Case Comprehensive Cancer Center
Fuda Cancer Hospital, Guangzhou
Lumos Pharma
NYU Langone Health
Abramson Cancer Center at Penn Medicine
Acrotech Biopharma Inc.
Biomoda Inc.
Fuda Cancer Hospital, Guangzhou
Fuda Cancer Hospital, Guangzhou
Fuda Cancer Hospital, Guangzhou
Fuda Cancer Hospital, Guangzhou
H. Lee Moffitt Cancer Center and Research Institute
Michigan State University